Skip to main content


You are here

National Cancer Institute Accepts Rexahn's RX-21101 for Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program

Monday, June 8, 2015

Program Will Provide Foundation for Filing an IND Application for Phase I Trial

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that its drug candidate RX-21101 was selected by the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL) for its preclinical characterization program to help facilitate the advance of RX-21101 towards human clinical trials. RX-21101 is a polymer conjugated form of docetaxel that contains a signaling moiety which directs the drug into the tumor. This approach may maximize the level of docetaxel in the tumor and may minimize the level of freely circulating docetaxel in the body, which may result in increased anti-tumor activity and a reduction of adverse events. 

RX-21101 was developed using the Nano-Polymer-Drug Conjugate Systems (NPDCS) platform jointly discovered with the University of Maryland at Baltimore. This technology targets the delivery of docetaxel directly into cancerous tumors. The direct delivery of chemotherapeutic drugs into the tumors has been shown to result in increased efficacy and reduced toxicity in preclinical studies.

Click here to read more.